Sven Brandau

Dr. Sven Brandau received his doctoral degree in 1996 from the Bernhard-Nocht-Institute for Tropical Medicine. Since 2009, he has been working as an Associate Professor at the University Duisburg-Essen. Sven´s main research area is the immunological tumor-host interaction with a focus on myeloid cells. Additional research projects aim at developing novel immunotherapies for head and neck cancer and investigating the role of mesenchymal stromal cells in cancer and infection.

Lab Information

University of Duisburg-Essen

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Immunology 0 Immunotherapies 0 Head and Neck Cancer 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (0)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel

  2. P, Lang S. (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients

  3. contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol. 89(2),

  4. 311-317

  5. Bergmann C, Wild CA, Narwan M, Lotfi R, Lang S, Brandau S (2011) Human tumor-induced Treg and

  6. naturally occurring Treg differentially affect NK cells activated by interleukin-2 or target cells. Eur J

  7. Immunol 41(12), 3564-73

  8. Davey MS, Tamassia N, Rossato M, Bazzoni F, Calzetti F, Bruderek K, Sironi M, Zimmer L, Bottazzi B,

  9. Mantovani A, Brandau S, Moser B, Eberl M, Cassatella MA. (2011) Failure to detect production of

  10. IL-10 by activated human neutrophils. Nat Immunol. (correspondence) 12(11):1017-8.

  11. Dumitru CA, Fechner MK, Hoffmann TK, Lang S, Brandau S. (2012) A Novel p38-MAPK Signaling Axis

  12. Modulates Neutrophil Biology in Head and Neck Cancer. J Leukoc Biol. 91 (4), 591-599

  13. Hasenberg A, Hasenberg M, Männ L, Neumann F, Borkenstein L, Stecher M, Kraus A, Engel DR, Klingberg A,

  14. Seddigh P, Abdullah Z, Klebow S, Engelmann S, Reinhold A, Brandau S, Seeling M, Waisman A,

  15. Schraven B, Göthert JR, Nimmerjahn F, Gunzer M. (2015) Catchup: a mouse model for imagingbased tracking and modulation of neutrophil granulocytes. Nat Methods. 12(5):445-52


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists


This guy has no follower now.

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud